/stocks — the workspaceLOADING
All SBFM SEC filings, by type → · Earnings date & implied move · Search inside filings
Sunshine Biopharma Inc. (SBFM) is a pharmaceutical preparations company. Piotroski F-Score 5/8. 1 insider Form 4 filings in the last 90 days. Next earnings projected around 2027-04-08 from SBFM's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
What’s behind SBFM’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
FY ending 2025-12-31 vs 2024-12-31.
No sensitivity grid: free cash flow is not positive, so the DCF gives no value at any growth or discount rate.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from SBFM’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on SBFM plus an auto-SWOT — built from SBFM's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate SBFM using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has SBFM been issuing shares? Offering history →
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as SBFM tagged it: revenue us-gaap:Revenues, net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
Projected from SBFM's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentSBFM files or announces.
SBFM has sold off after 3 of its last 5 earnings reports.
Each figure is one earnings reaction — how much SBFM moved from the closing price the day before a report to the close the day after. Based on its last 5 reports.
Earnings reactions have been moderate.
SBFM has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+2.1% and -11.5%).
A more typical earnings reaction has been approximately ±2.1%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-04-09 | -4.9% |
| 2025-05-19 | -0.3% |
| 2025-04-02 | -11.5% |
| 2024-11-07 | +0.4% |
| 2024-08-19 | +2.1% |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
No tracked institution reported a position in SBFM in the latest 13F round.
No lawmaker has disclosed a trade in SBFM under the STOCK Act.
None of the 5 estimators could run on SBFM's filings.
One estimator is a point estimate, not a range, so no band and no valuation label are published for SBFM. Below is everything that was checked, so the refusal can be read rather than taken on trust.
Nothing produced a value.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for SBFM, so sector medians could not fill the gaps.
Every refusal recorded for SBFM → · How often we decline, and why →
No open-market Form 4 buys or sells reported for SBFM in the last ~6 months.
2 of the 2 checks that ran found nothing new for SBFM. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
Head office: Fort Lauderdale, Florida, United States · the company’s charter and its head office are in different states.
Source: the cover page of Sunshine Biopharma Inc.’s 10-Q filed 2026-08-13, on EDGAR. Filings checked 2026-10-21. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works